Proteasome inhibition and its therapeutic potential in multiple myeloma
Ajai Chari1, Amitabha Mazumder2, Sundar Jagannath11Mount Sinai School of Medicine, New York, NY, USA; 2New York University School of Medicine, New York, NY, USAAbstract: Due to an unmet clinical need for treatment, the first in class proteasome inhibitor, bortezomib, moved from drug discovery to FDA...
Guardado en:
Autores principales: | Ajai Chari, Amitabha Mazumder, Sundar Jagannath |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bfa5dae794bc4d58b562ef9039d50e04 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Quantitative phosphoproteomics of proteasome inhibition in multiple myeloma cells.
por: Feng Ge, et al.
Publicado: (2010) -
Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma
por: Hector H. Huang, et al.
Publicado: (2020) -
Profile of elotuzumab and its potential in the treatment of multiple myeloma
por: Liu YC, et al.
Publicado: (2014) -
Front line treatment of elderly multiple myeloma in the era of novel agents
por: Marie-Dominique Venon, et al.
Publicado: (2008) -
Relapsed and refractory lymphoid neoplasms and multiple myeloma with a focus on carfilzomib
por: Nooka A, et al.
Publicado: (2013)